Chronic Dexamethasone Treatment: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Rita Xu and Version 1 by MARTA MONZON.

Neuroinflammation has been correlated with the progress of neurodegeneration in many neuropathologies. Although glial cells have traditionally been considered to be protective, the concept of them as neurotoxic cells has recently emerged. Thus, a major unsolved question is the exact role of astroglia and microglia in neurodegenerative disorders. On the other hand, it is well known that glucocorticoids are the first choice to regulate inflammation and, consequently, neuroglial inflammatory activity. The objective of this study was to determine how chronic dexamethasone treatment influences the host immune response and to characterize the beneficial or detrimental role of glial cells. To date, this has not been examined using a natural neurodegenerative model of scrapie. With this aim, immunohistochemical expression of glial markers, prion protein accumulation, histopathological lesions and clinical evolution were compared with those in a control group. Although impact of dexamethasone administration on neuropathological lesions was not demonstrated and treatment did not seem to be clinically relevant to disease progress when clinical signs had already begun, the evident extension of survival in one case was hopeful. T

he findings presented in this study support a potential failure of astrocytes and a stimulation of phagocytosis of PrPsc deposits by microglia.

Thus, it is evidenced here how the complex interaction between glial populations failed to compensate for brain damage in natural conditions, emphasizing the need for using natural models. Additionally, the data showed that modulation of neuroinflammation by anti-inflammatory drugs might become a research focus as a potential therapeutic target for prion diseases, similar to that considered previously for other neurodegenerative disorders classified as prion-like diseases.

  • dexamethasone
  • neuroinflammation
  • astrocytes
  • microglia
  • prion diseases
  • neurodegeneration
Please wait, diff process is still running!

References

  1. Diego Gomez-Nicola; Nina L. Fransen; Stefano Suzzi; V. Hugh Perry; Regulation of Microglial Proliferation during Chronic Neurodegeneration. The Journal of Neuroscience 2013, 33, 2481-2493, 10.1523/JNEUROSCI.4440-12.2013.
  2. James A. Carroll; Brent Race; Katie Williams; James Striebel; Bruce Chesebro; Microglia Are Critical in Host Defense against Prion Disease. Journal of Virology 2018, 92, e00549-18, 10.1128/jvi.00549-18.
  3. Mariagrazia Grilli; M Memo; Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochemical Pharmacology 1999, 57, 1–7.
  4. Liudmila Efremova; Petra Chovancova; Martina Adam; Simon Gutbier; Stefan Schildknecht; Marcel Leist; Switching from astrocytic neuroprotection to neurodegeneration by cytokine stimulation. Archives of Toxicology 2017, 91, 231-246, 10.1007/s00204-016-1702-2.
  5. Iwona Kurkowska-Jastrzebska; Tomasz Litwin; Ilona Joniec-Maciejak; Agnieszka Ciesielska; Adam Przybyłkowski; A. Czlonkowski; Anna Czlonkowska; Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. International Immunopharmacology 2004, 4, 1307-1318, 10.1016/j.intimp.2004.05.006.
  6. Green, K.N.; Billings, L.M.; Roozendaal, B.; McGaugh, J.L.; LaFerla, F.M. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer’s disease. J. Neurosci. 2006, 26, 9047–9056.
  7. Michal Schnaider Beeri; James Schmeidler; Gerson T. Lesser; Maria Maroukian; Rebecca West; Stephanie Leung; Michael Wysocki; Daniel P. Perl; Dushyant P. Purohit; Vahram Haroutunian; et al. Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology. Neurobiology of Aging 2012, 33, 1258-1264, 10.1016/j.neurobiolaging.2011.02.011.
  8. Michael Nerius; Britta Haenisch; Willy Gomm; Gabriele Doblhammer; Anja Schneider; Glucocorticoid Therapy is Associated with a Lower Risk of Dementia. Journal of Alzheimer's Disease 2020, 73, 175-183, 10.3233/jad-190444.
  9. G. W. Outram; A. G. Dickinson; H. Fraser; Reduced susceptibility to scrapie in mice after steroid administration. Nature 1974, 249, 855-856, 10.1038/249855a0.
  10. Constanze Riemer; Michael Burwinkel; Anja Schwarz; Sandra Gültner; Simon W. F. Mok; Ines Heise; Nikola Holtkamp; Michael Baier; Evaluation of drugs for treatment of prion infections of the central nervous system. Journal of General Virology 2008, 89, 594-597, 10.1099/vir.0.83281-0.
  11. Bruno Pietro Imbimbo; An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. Expert Opinion on Investigational Drugs 2009, 18, 1147-1168, 10.1517/13543780903066780.
  12. Denise Tischner; Holger M. Reichardt; Glucocorticoids in the control of neuroinflammation. Molecular and Cellular Endocrinology 2007, 275, 62-70, 10.1016/j.mce.2007.03.007.
  13. Le Min; F. Stephen Hodi; Ursula B. Kaiser; Corticosteroids and immune checkpoint blockade. Aging 2015, 7, 521-522, 10.18632/aging.100797.
  14. Allan Munck; Anikó Náray-Fejes-Tóth; The ups and downs of glucocorticoid physiology Permissive and suppressive effects revisited. Molecular and Cellular Endocrinology 1992, 90, C1-C4, 10.1016/0303-7207(92)90091-j.
  15. L. P. Filaretova; T. Podvigina; T. Bagaeva; O. Morozova; Dual action of glucocorticoid hormones on the gastric mucosa: how the gastroprotective action can be transformed to the ulcerogenic one. Inflammopharmacology 2009, 17, 15-22, 10.1007/s10787-008-8046-3.
  16. Shawn Sorrells; Javier R. Caso; Carolina D. Munhoz; Robert M. Sapolsky; The Stressed CNS: When Glucocorticoids Aggravate Inflammation. Neuron 2009, 64, 33-39, 10.1016/j.neuron.2009.09.032.
  17. Spies, C.M.; Strehl, C.; van der Goes, M.C.; Bijlsma, J.W.; Buttgereit, F; Glucocorticoids. Best Pract Res. Clin. Rheumatol. 2011, 25, 891–900.
  18. John R. Kirwan; Glucocorticoid resistance in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 2007, 36, 165-166, 10.1080/03009740701340263.
  19. Edo R. De Kloet; Brain Corticosteroid Receptor Balance in Health and Disease. Endocrine Reviews 1998, 19, 269-301, 10.1210/er.19.3.269.
  20. O. C. Meijer; Penetration of Dexamethasone into Brain Glucocorticoid Targets Is Enhanced in mdr1A P-Glycoprotein Knockout Mice. Endocrinology 1998, 139, 1789-1793, 10.1210/en.139.4.1789.
  21. Cara Hueston; Terrence Deak; The inflamed axis: The interaction between stress, hormones, and the expression of inflammatory-related genes within key structures comprising the hypothalamic–pituitary–adrenal axis. Physiology & Behavior 2014, 124, 77-91, 10.1016/j.physbeh.2013.10.035.
  22. Amber J. Giles; Marsha-Kay N. D. Hutchinson; Heather Sonnemann; Jinkyu Jung; Peter E. Fecci; Nivedita M. Ratnam; Wei Zhang; Hua Song; Rolanda Bailey; Dionne Davis; Caitlin M. Reid; Deric M. Park; Mark R. Gilbert; Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. Journal for ImmunoTherapy of Cancer 2018, 6, 51, 10.1186/s40425-018-0371-5.
  23. Günther Weindl; M. Schaller; Monika Schäfer-Korting; H.C. Korting; Hyaluronic Acid in the Treatment and Prevention of Skin Diseases: Molecular Biological, Pharmaceutical and Clinical Aspects. Skin Pharmacology and Physiology 2004, 17, 207-213, 10.1159/000080213.
  24. Michael W. Whitehouse; Anti-inflammatory glucocorticoid drugs: reflections after 60 years. Inflammopharmacology 2011, 19, 1-19, 10.1007/s10787-010-0056-2.
  25. Rodrigo S. Hernández; Rocío Sarasa; Adolfo Toledano; Juan J. Badiola; Marta Monzón; Morphological approach to assess the involvement of astrocytes in prion propagation. Cell and Tissue Research 2014, 358, 57-63, 10.1007/s00441-014-1928-3.
  26. Monzón, M.; Hernández, R.S.; Garcés, M.; Sarasa, R.; Badiola, J.J. Glial alterations in human prion diseases, a correlative study of astroglia, reactive microglia, protein deposition, and neuropathological lesions. Medicine (Baltimore) 2018, 97, e0320.
  27. Justyna R Sarna; Richard Hawkes; Patterned Purkinje cell death in the cerebellum. Progress in Neurobiology 2003, 70, 473-507, 10.1016/s0301-0082(03)00114-x.
  28. Rocío Sarasa; Concepción Junquera; Adolfo Toledano; Juan José Badiola; Marta Monzón; Ultrastructural changes in the progress of natural Scrapie regardless fixation protocol. Histochemistry and Cell Biology 2015, 144, 77-85, 10.1007/s00418-015-1314-6.
  29. Stephane Lezmi; T. Seuberlich; Anna Oevermann; T. Baron; Anna Bencsik; Comparison of Brain PrPd Distribution in Ovine BSE and Scrapie. Veterinary Pathology 2011, 48, 1101-1108, 10.1177/0300985810395784.
  30. James Alibhai; Richard A. Blanco; Marcelo A. Barria; Pedro Piccardo; Byron Caughey; V. Hugh Perry; Tom C Freeman; Jean Manson; Distribution of Misfolded Prion Protein Seeding Activity Alone Does Not Predict Regions of Neurodegeneration. PLoS Biology 2016, 14, e1002579, 10.1371/journal.pbio.1002579.
  31. Rocío Sarasa; Alfredo Martinez; Eva Monleón; Rosa Bolea; Antonia Vargas; Juan José Badiola; Marta Monzón; Involvement of astrocytes in transmissible spongiform encephalopathies: a confocal microscopy study. Cell and Tissue Research 2012, 350, 127-134, 10.1007/s00441-012-1461-1.
  32. Moisés Garcés; M. Isabel Guijarro; Antonia Vargas; Juan J. Badiola; Marta Monzón; Neuroglial patterns are shared by cerebella from prion and prion-like disorder affected patients.. Mechanisms of Ageing and Development 2019, 184, 111176, 10.1016/j.mad.2019.111176.
  33. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; et al.et al Inflammation and Alzheimer’s disease. Neurobiol. Aging 2000, 21, 383–421.
  34. Verkhratsky, A.; Marutle, A.; Rodriguez-Arellano, J.J.; Nordberg, A. Glial Asthenia and Functional Paralysis, A New Perspective on Neurodegeneration and Alzheimer’s Disease. Neuroscientist 2015, 21, 552–568.
  35. Alexei Verkhratsky; Jose Julio Rodrigues; Augustas Pivoriunas; Robert Zorec; Alexey Semyanov; Astroglial atrophy in Alzheimer's disease.. Pflüger, Archiv für die Gesammte Physiologie des Menschen und der Thiere 2019, 471, 1247-1261, 10.1007/s00424-019-02310-2.
  36. A. Williams; P.J. Lucassen; D. Ritchie; M. Bruce; PrP Deposition, Microglial Activation, and Neuronal Apoptosis in Murine Scrapie. Experimental Neurology 1997, 144, 433-438, 10.1006/exnr.1997.6424.
  37. H. Fraser; K. L. Brown; K. Stewart; I. McConnell; P. McBride; A. Williams; Replication of scrapie in spleens of SCID mice follows reconstitution with wild-type mouse bone marrow. Journal of General Virology 1996, 77, 1935-1940, 10.1099/0022-1317-77-8-1935.
  38. J Berciano; M T Berciano; J M Polo; J Figols; J Ciudad; Vanesa Lafarga; Creutzfeldt-Jakob disease with severe involvement of cerebral white matter and cerebellum.. Virchows Arch. Pathol. Anat. Histopathol. 1990, 417, 36–45.
  39. Armstrong, R.A.; Ironside, J.W.; Lantos, P.L.; Cairns, N.J. A quantitative study of the pathological changes in the cerebellum in 15 cases of variant Creutzfeldt-Jakob disease (vCJD). Neuropathol. Appl. Neurobiol. 2009, 35, 36–45.
  40. Ignazio Cali; Cathleen J. Miller; Joseph E. Parisi; Michael D. Geschwind; Pierluigi Gambetti; Lawrence B. Schonberger; Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone. Acta Neuropathologica Communications 2015, 3, 37, 10.1186/s40478-015-0214-2.
  41. María-Isabel Álvarez; Luis Rivas; César Lacruz; Adolfo Toledano Gasca; Astroglial cell subtypes in the cerebella of normal adults, elderly adults, and patients with Alzheimer's disease: A histological and immunohistochemical comparison. Glia 2015, 63, 287-312, 10.1002/glia.22751.
  42. Zeug, A.; Muller, F.E.; Anders, S.; Herde, M.K.; Minge, D.; Ponimaskin, E.; Henneberger, C; Control of astrocyte morphology by Rho GTPases. Brain Res. Bull. 2018, 126, 44–53.
  43. Hugh V. Perry; Colm Cunningham; Delphine Boche; Atypical inflammation in the central nervous system in prion disease. Current Opinion in Neurology 2002, 15, 349-354, 10.1097/00019052-200206000-00020.
  44. V. Hugh Perry; Vincent O'connor; The Role of Microglia in Synaptic Stripping and Synaptic Degeneration: A Revised Perspective. ASN Neuro 2010, 2, 281-291, 10.1042/AN20100024.
  45. G. Meneses; G. Gevorkian; A. Florentino; M. A. Bautista; A. Espinosa; G. Acero; G. Díaz; A. Fleury; I. N. Pérez Osorio; A. Del Rey; G. Fragoso; Edda Sciutto; H. Besedovsky; Intranasal delivery of dexamethasone efficiently controls LPS‐induced murine neuroinflammation. Clinical & Experimental Immunology 2017, 190, 304-314, 10.1111/cei.13018.
  46. Hui, B.; Yao, X.; Zhang, L.; Zhou, Q. Dexamethasone sodium phosphate attenuates lipopolysaccharide-induced neuroinflammation in microglia BV2 cells. Naunyn Schmiedebergs Arch. Pharmacol. 2020.
  47. Duque Ede, A.; Munhoz, C.D; The Pro-inflammatory Effects of Glucocorticoids in the Brain. Front. Endocrinol (Lausanne) 2016, 7, 78.
  48. Richard M. Ransohoff; V. Hugh Perry; Microglial Physiology: Unique Stimuli, Specialized Responses. Annual Review of Immunology 2009, 27, 119-145, 10.1146/annurev.immunol.021908.132528.
  49. Delphine Boche; V. H. Perry; J. A. R. Nicoll; Review: Activation patterns of microglia and their identification in the human brain. Neuropathology and Applied Neurobiology 2013, 39, 3-18, 10.1111/nan.12011.
  50. Streit, W.J.; Xue, Q.S.; Tischer, J.; Bechmann, I; Microglial pathology. Acta Neuropathol. Commun. 2014, 2, 142.
  51. Kim, S.U.; de Vellis, J; Microglia in health and disease. J. Neurosci. Res. 2005, 81, 302–313.
  52. H. Mühleisen; J. Gehrmann; R. Meyermann; Reactive microgIia in Creutzfeldt-Jakob disease. Neuropathology and Applied Neurobiology 1995, 21, 505-517, 10.1111/j.1365-2990.1995.tb01097.x.
  53. Franc Llorens; Irene Lã³Pez-Gonzã¡lez; Katrin Thã¼Ne; Margarita Carmona; Saima Zafar; Olivier Andrã©Oletti; Inga Zerr; Isidre Ferrer; Irene López-González; Katrin Thüne; et al.Olivier Andréoletti Subtype and Regional-Specific Neuroinflammation in Sporadic Creutzfeldt–Jakob Disease. Frontiers in Aging Neuroscience 2014, 6, 198, 10.3389/fnagi.2014.00198.
  54. Diana M. Norden; Paige J. Trojanowski; Emmanuel Villanueva; Elisa Navarro; Jonathan P. Godbout; Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge. Glia 2016, 64, 300-16, 10.1002/glia.22930.
  55. Carroll, J.A.; Chesebro, B; Neuroinflammation, Microglia, and Cell-Association during Prion Disease. Viruses 2019, 11, 65.
  56. DiSabato, D.J.; Quan, N.; Godbout, J.P; Neuroinflammation, the devil is in the details. J. Neurochem. 2016, 139, 136–153.
  57. Obst, J.; Simon, E.; Mancuso, R.; Gomez-Nicola, D; The Role of Microglia in Prion Diseases, A Paradigm of Functional Diversity. Front. Aging Neurosci. 2017, 9, 207.
  58. Liberski, P.P.; Sklodowski, P.; Klimek, A; Creutzfeldt-Jakob disease, ultrastructural study of brain biopsy, unusual interaction between astrocytes and oligo- and microglia. Folia. Neuropathol. 1995, 33, 85–92.
  59. Kordek, R.; Nerurkar, V.R.; Liberski, P.P.; Isaacson, S.; Yanagihara, R.; Gajdusek, D.C; Heightened expression of tumor necrosis factor alpha, interleukin 1 alpha, and glial fibrillary acidic protein in experimental Creutzfeldt-Jakob disease in mice. Proc. Natl. Acad. Sci. USA 1996, 93, 9754–9758.
  60. Buffo, A.; Rolando, C.; Ceruti, S; Astrocytes in the damaged brain, molecular and cellular insights into their reactive response and healing potential. Biochem. Pharmacol. 2010, 79, 77–89.
  61. Garwood, C.J.; Pooler, A.M.; Atherton, J.; Hanger, D.P.; Noble, W; Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis. 2011, 2, e167.
  62. Shane A. Liddelow; Ben A. Barres; Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity 2017, 46, 957-967, 10.1016/j.immuni.2017.06.006.
  63. Shane A. Liddelow; Kevin A. Guttenplan; Laura E. Clarke; F. Chris Bennett; Christopher J. Bohlen; Lucas Schirmer; Mariko L. Bennett; Alexandra E. Münch; Won-Suk Chung; Todd C. Peterson; et al.Daniel K. WiltonArnaud FrouinBrooke A. NapierNikhil PanickerManoj KumarMarion S. BuckwalterDavid H. RowitchValina L. DawsonTed M. DawsonBeth StevensBen A. Barres Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017, 541, 481-487, 10.1038/nature21029.
  64. Kelly S. Kirkley; Katriana A. Popichak; Maryam F. Afzali; Marie E. Legare; Ronald B. Tjalkens; Microglia amplify inflammatory activation of astrocytes in manganese neurotoxicity. Journal of Neuroinflammation 2017, 14, 99, 10.1186/s12974-017-0871-0.
  65. Espinosa, J.C.; Nonno, R.; Di Bari, M.; Aguilar-Calvo, P.; Pirisinu, L.; Fernandez-Borges, N.; Vanni, I.; Vaccari, G.; Marin-Moreno, A.; Frassanito, P.; et al.et al PrPC Governs Susceptibility to Prion Strains in Bank Vole, While Other Host Factors Modulate Strain Features. J. Virol. 2016, 90, 10660–10669.
  66. Candace K. Mathiason; Scrapie, CWD, and Transmissible Mink Encephalopathy. Progress in Molecular Biology and Translational Science 2017, 150, 267-292, 10.1016/bs.pmbts.2017.07.009.
  67. Jasna Kriz; Minh Dang Nguyen; Jean-Pierre Julien; Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis.. Neurobiology of Disease 2002, 10, 268-278, 10.1006/nbdi.2002.0487.
  68. Paul Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; et al.Hans E NevilleKevin BoylanTahseen MozaffarJerry M BelshJohn RavitsRichard S BedlackMichael C GravesLeo F McCluskeyRichard J BarohnRup Tandan Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. The Lancet Neurology 2007, 6, 1045-1053, 10.1016/s1474-4422(07)70270-3.
  69. Ji-Kyung Choi; Bruce G. Jenkins; Isabel Carreras; Sukru Kaymakcalan; Kerry Cormier; Neil W. Kowall; Alpaslan Dedeoglu; Anti-inflammatory treatment in AD mice protects against neuronal pathology. Experimental Neurology 2010, 223, 377-384, 10.1016/j.expneurol.2009.07.032.
  70. Aisen, P.S.; Schafer, K.A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K.L.; Farlow, M.R.; Jin, S.; Thomas, R.G.; Thal, L.J; et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression, a randomized controlled trial. JAMA 2003, 289, 2819–2826.
  71. Michael Burwinkel; Constanze Riemer; Anja Schwarz; Julia Schultz; Sabine Neidhold; Theresa Bamme; Michael Baier; Role of cytokines and chemokines in prion infections of the central nervous system. International Journal of Developmental Neuroscience 2004, 22, 497-505, 10.1016/j.ijdevneu.2004.07.017.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback